{"preliminary_commentary":{"by_channel":{"x_thread":28,"youtube":5,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04443062\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["177Lu-PSMA-617"]],"indication":"oligometastatic hormone-sensitive prostate cancer","name":"BULLSEYE","nct_id":"NCT04443062","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=bullseye-nct04443062. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"Bullseye","arms":[{"description":"2 (+2) cycles of 7.4 GBq 177Lu-PSMA 6 weeks in between","label":"Interventional arm: 177Lu-PSMA radioligand therapy","type":"EXPERIMENTAL"},{"description":"Deferred androgen deprivation therapy. However, the control arm can receive the study drug (177Lu-PSMA) in case of disease progression (defined in the study protocol).","label":"Standard of care","type":"NO_INTERVENTION"}],"collaborators":["Prostaatkankerstichting","Advanced Accelerator Applications"],"completion_date":{"date":"2026-01-01","type":"ACTUAL"},"conditions":["Prostate Cancer"],"enrollment":{"count":58,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"177Lu-PSMA-617","otherNames":[],"type":"DRUG"}],"last_update":"2026-02-27","lead_sponsor":"Radboud University Medical Center","official_title":"Lutetium-177-PSMA-617 Radioligand Therapy in Oligo-metastatic Hormone Sensitive Prostate Cancer.","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-04-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"To compare the fraction of patients that have disease progression (and meet EOT 1) criteria within 6 months in a group of patients that are treated with 177Lu-PSMA and a group that follows the current standard of care.","timeFrame":"30 weeks"},{"measure":"A second primary aim is to compare the two arms for the time to disease progression and meeting EOT 1 criteria.","timeFrame":"30 weeks"}],"references":[{"citation":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lutzen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bogemann M, Fendler WP, Krause BJ. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med. 2017 Jan;58(1):85-90. doi: 10.2967/jnumed.116.183194. Epub 2016 Oct 20.","pmid":"27765862","type":"BACKGROUND"},{"citation":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8.","pmid":"29752180","type":"BACKGROUND"},{"citation":"Prive BM, Noordzij W, Muselaers CHJ, de Jong IJ, van Oort IM, Janssen MJR, Van Rijk MC, van Gemert WA, Timmermans B, de Groot M, Mehra N, Gerritsen WR, Jonker MA, Alevroudis E, van der Gaag S, Koppes JCC, Sedelaar JPM, Vis AN, Vrachimis A, Oprea-Lager DE, Nagarajah J. [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study. Lancet Oncol. 2026 Apr;27(4):461-469. doi: 10.1016/S1470-2045(25)00762-4.","pmid":"41926960","type":"DERIVED"},{"citation":"Prive BM, Janssen MJR, van Oort IM, Muselaers CHJ, Jonker MA, van Gemert WA, de Groot M, Westdorp H, Mehra N, Verzijlbergen JF, Scheenen TWJ, Zamecnik P, Barentsz JO, Gotthardt M, Noordzij W, Vogel WV, Bergman AM, van der Poel HG, Vis AN, Oprea-Lager DE, Gerritsen WR, Witjes JA, Nagarajah J. Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. Trials. 2021 Nov 4;22(1):768. doi: 10.1186/s13063-021-05733-4.","pmid":"34736509","type":"DERIVED"},{"citation":"Prive BM, Janssen MJR, van Oort IM, Muselaers CHJ, Jonker MA, de Groot M, Mehra N, Verzijlbergen JF, Scheenen TWJ, Zamecnik P, Barentsz JO, Gotthardt M, Noordzij W, Vogel WV, Bergman AM, van der Poel HG, Vis AN, Oprea-Lager DE, Gerritsen WR, Witjes JA, Nagarajah J. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. BMC Cancer. 2020 Sep 14;20(1):884. doi: 10.1186/s12885-020-07386-z.","pmid":"32928177","type":"DERIVED"}],"start_date":{"date":"2020-07-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT04443062"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/bullseye-nct04443062"}